Wikisage, the free encyclopedia of the second generation, is digital heritage
Flibanserin: Difference between revisions
Jump to navigation
Jump to search
(type) |
(rfz) |
||
| Line 3: | Line 3: | ||
treatment of HSDD in premenopausal women.<ref>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf</ref> | treatment of HSDD in premenopausal women.<ref>http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM449088.pdf</ref> | ||
<gallery>File:flibanserin-structural.svg.png</gallery> | <gallery>File:flibanserin-structural.svg.png</gallery> | ||
==Links== | |||
http://jama.jamanetwork.com/article.aspx?articleid=2389384 Evaluation of Flibanserin Science and Advocacy at the FDA | |||
<references/> | <references/> | ||
Revision as of 18:08, 19 August 2015
fibraserin is a new FDA aproved drug. Former developed in Europe by Boeringer Ingelheim latter in US by Sprout Pharmaceutical due it refusal by Health Authory in 2013[1]Flibanserin is a post-synaptic 5-hydroxytryptamine (5-HT) 1A receptor agonist and 5-HT 2A antagonist that has been evaluated for indications of major depressive disorder (MDD) and for the treatment of HSDD in premenopausal women.[2]
Links
http://jama.jamanetwork.com/article.aspx?articleid=2389384 Evaluation of Flibanserin Science and Advocacy at the FDA